Systemic therapies for mucopolysaccharidosis: Ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy - a review

Clinical and Experimental Ophthalmology

Volumn 38, Issue SUPPL. 1, 2010, Pages 34-42

  Summers, C Gail ^a   Fahnehjelm, Kristina T ^b   Pitz, Susanne ^c   Guffon, Nathalie ^d   Koseoglu, Selim T ^e   Harmatz, Paul ^e   Scarpa, Maurizio ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HOSPICES CIVILS DE LYON   (France)

^e CHILDREN S HOSPITAL OAKLAND   (United States)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Enzyme replacement therapy; Eye manifestation; Hematopoietic stem cell transplantation; Mucopolysaccharidosis; Therapeutic

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CORTICOSTEROID; GALSULFASE; IDURONATE 2 SULFATASE; LARONIDASE; LYSOSOME ENZYME; RECOMBINANT ENZYME; SOMATOMEDIN B RECEPTOR; STEROID;

ADVERSE OUTCOME; CHILD; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME REPLACEMENT; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; INTRACELLULAR TRANSPORT; KERATOCONJUNCTIVITIS SICCA; LYSOSOME; MUCOPOLYSACCHARIDOSIS; PATIENT SAFETY; PROTEIN FUNCTION; RETINA DEGENERATION; REVIEW; STEROID THERAPY; SUBCAPSULAR CATARACT; THERAPY EFFECT; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 77955370623     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02366.x     Document Type: Review

References (41)

1. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006, 51:1-17.
2. Ferrari S, Ponzin D, Ashworth JL. Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis. Br J Ophthalmol 2010, doi:10.1136/bjo.2010.179937
3. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007, 120:405-18.
4. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 2007, 121:1-22.
5. Ashworth JL, Kruse FE, Bachmann B. Ocular manifestations in the mucopolysaccharidoses. Clin Experiment Ophthalmol 2010, 38(S1):12-22.
6. Kornfeld S, Mellman I. The biogenesis of lysosomes. Annu Rev Cell Biol 1989, 5:483-525.
7. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003, 4:202-12.
8. Kornfeld S. Trafficking of lysosomal enzymes in normal and disease states. J Clin Invest 1986, 77:1-6.
9. Muenzer J, Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med 2004, 350:1932-4.
10. Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br J Haematol 2010, 148:356-72.
11. Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009, 123:19-29.
12. Martins AM, Dualibi AP, Norato D. Guidelines for the management of mucopolysaccharidosis type I. J Pediatr 2009, 155:S32-46.
13. Grigull L, Beilken A, Schrappe M. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler). Bone Marrow Transplant 2005, 35:265-9.
14. Staba SL, Escolar ML, Poe M. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004, 350:1960-9.
15. Summers CG, Purple RL, Krivit W. Ocular changes in the mucopolysaccharidoses after bone marrow transplantation. A preliminary report. Ophthalmology 1989, 96:977-85.
16. Baehner F, Schmiedeskamp C, Krummenauer F. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005, 28:1011-17.
17. Lin HY, Lin SP, Chuang CK. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009, 149A:960-4.
18. Muenzer J, Beck M, Eng CM. Multidisciplinary management of Hunter syndrome. Pediatrics 2009, 124:e1288-39.
19. Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 2009, 154:733-7.
20. Gullingsrud EO, Krivit W, Summers CG. Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology 1998, 105:1099-105.
21. Vellodi A, Young EP, Cooper A. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 1997, 76:92-9.
22. Willoughby CE, Ponzin D, Ferrari S, Lobo A, Landau K, Omidi Y. Anatomy and physiology of the human eye: effects of mucopolysaccharidosis disease on structure and function. Clin Experiment Ophthalmol 2010, 38(S1):2-11.
23. Grewal SS, Krivit W, Defor TE. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone Marrow Transplant 2002, 29:491-6.
24. Fleming DR, Henslee-Downey PJ, Ciocci G. The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I. Pediatr Transplant 1998, 2:299-304.
25. Fahnehjelm KT, Törnquist AL, Malm G, Winiarski J. Ocular findings in four children with mucopolysaccharidosis I-Hurler (MPS I-H) treated early with haematopoietic stem cell transplantation. Acta Ophthalmol Scand 2006, 84:781-5.
26. Rohrbach M, Clarke JTR. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 2007, 67:2697-716.
27. Harmatz P, Giugliani R, Schwartz I. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006, 148:533-9.
28. Harmatz P, Giugliani R, Schwartz IVD. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 2008, 94:469-75.
29. Muenzer J, Wraith JE, Beck M. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006, 8:465-73.
30. Clarke LA, Wraith JE, Beck M. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009, 123:229-40.
31. Wraith JE, Clarke LA, Beck M. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr 2004, 144:581-8.
32. Kakkis ED, Muenzer J, Tiller GE. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001, 344:182-8.
33. Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 2005, 6:489-506.
34. Pitz S, Ogun O, Bajbouj M, Arash L, Schulze-Frenking G, Beck M. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol 2007, 125:1353-6.
35. Schumacher RG, Brzezinska R, Schulze-Frenking G, Pitz S. Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatr Radiol 2008, 38:543-50.
36. Scarpa M, Barone R, Fiumara A. Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 2009, 168:1203-6.
37. Pitz S, Ogun O, Arash L, Miebach E, Beck M. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch Clin Exp Ophthalmol 2009, 247:975-80.
38. Koseoglu ST, Harmatz P, Turbeville S, Nicely H. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme®) therapy. Int Ophthalmol 2009, 29:267-9.
39. Wraith JE, Scarpa M, Beck M. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008, 167:267-77.
40. Pastores GM, Arn P, Beck M. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab 2007, 91:37-47.
41. Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter Outcome Survey. Genet Med 2008, 10:508-16.